Pfizer and BioNTech have announced what the world has been waiting for – positive interim Phase III results for their mRNA-based COVID-19 vaccine, BNT162b2, suggesting that it is 90% effective in preventing infection.
While the full data have yet to be published in a peer-reviewed journal, the topline result is a huge step...
Welcome to Scrip
Create an account to read this article
Already a subscriber?